Dementia Australia is disappointed by the initial decision of the Therapeutic Goods Administration (TGA) to reject Lecanemab for use in Australia. Lecanemab is a disease modifying treatment for people living with the early stages of Alzheimer’s disease or mild cognitive impairment. Developed by pharmaceutical company Eisai, Lecanemab works by removing amyloid plaques from the brain…
The post Rejection of drug a blow for Australians living with Alzheimer’s disease appeared first on The AIM Network.